Trials / Completed
CompletedNCT04502030
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Panzyga | Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2020-10-05
- Primary completion
- 2025-09-19
- Completion
- 2025-09-19
- First posted
- 2020-08-06
- Last updated
- 2025-10-03
Locations
84 sites across 12 countries: United States, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Russia, Spain, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04502030. Inclusion in this directory is not an endorsement.